Disclosed herein is a periscope device to provide forward viewing with a duodenoscope. The periscope device includes an elongated body and a deployment mechanism. The elongated body has a proximal end and a distal end. A folding axis of the elongated body defines an elongated section and a folding section of the elongated body. The folding section is located at the distal end of the elongated body and includes a mirror attached to an outer surface. The deployment mechanism is connected to the proximal end of the elongated body and is configured to cause the folding section to rotate about the folding axis at an angle of rotation with respect to the elongated section of the elongated body.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/273 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'appareil digestif supérieur, p. ex. œsophagoscopes, gastroscopes
2.
METHODS FOR EVALUATION OF EARLY STAGE ORAL SQUAMOUS CELL CARCINOMA
Provided here are methods of prognosis of oral squamous cell carcinoma in an individual, methods of providing decision support for suitable treatment regimens, and methods of monitoring responsiveness to treatment. These methods include the step of determining a high-risk epigenetic and clinicopathologic score for oral cancer from a sample from the individual. The sample can be a brush biopsy sample.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The subject technology relates generally to compositions and methods for producing plasmid DNA of a desired quality. In addition, it relates to the discovery of Escherichia coli (E. coli) bacteria with a constitutive methylase gene stably incorporated into the chromosomal DNA and uses thereof.
Provided here are compositions and methods for treatment of vascular conditions or respiratory conditions by administering a therapeutically effective amount of a nitrogen oxide compound and a nitrodilator. The nitrogen oxide compound can be nitrite, one or more of a number of nitro-group containing compounds, a nitrate-group containing compound, an NO donor, or an endogenous NO producing amino acid. The nitrodilator can be one or more of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, amyl nitrite, nitrosothiols, or dinitrosyl iron complexes.
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
Disclosed here are methods of evaluating resistance to a tyrosine kinase inhibitor (TKI) therapy of acute myeloid leukemia (AML) in a subject that include detecting the status of CD33, CD44, and phosphorylated BCL2 associated agonist of cell death (pBAD) expression. Also disclosed herein are methods of treating AML in a subject by administering a TKI and one or more inhibitors targeting a TKI-activated compensation pathway to the subject.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
An extremity drainage device, system, and method of use thereof are disclosed. The drainage device may be configured to collect a bodily fluid of a patient and/or a related irrigation fluid during a medical procedure. The drainage device may include a receptacle having a bottom surface and an outer wall extending upward from a perimeter of the bottom surface to an edge, the bottom surface and the outer wall defining a cavity. The edge may include a plurality of upper edge portions that substantially lie in a plane transverse to the outer wall and a plurality of lower edge portions, each lower edge portion connected to two upper edge portions. In addition, the lower edge portions may define in the outer wall at least two diametrically opposed side openings, each of the side openings having at least a partially curved profile at a bottom-most portion of the lower edge portion.
A61G 13/10 - Parties constitutives, détails ou accessoires
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A microanastomosis forceps including two longitudinally extending arms extending from a proximal pivot point. Each of the two longitudinally extending arms extends a predetermined length from the proximal pivot point to a respective distal end. A suction hose connection point adjacent to the proximal pivot point and one or more suction ports arranged on the distal end of at least one of the two longitudinally extending arms. A flow path is operably arranged between the suction hose and the one or more suction ports.
A61B 17/11 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour réaliser l'anastomoseBoutons pour anastomose
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
Provided here are compositions and methods for management of human papillomavirus-associated cancers. One such method of treating a human papillomavirus-associated cancer in a subject includes administering to the subject a therapeutically effective amount of gambogic acid or 30-hydroxygambogic acid or a pharmaceutically acceptable derivative thereof. These methods can also include administering one or more of radiation or a chemotherapeutic agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
Computer-implemented methods of neurovascular ultrasound analysis are disclosed for determination of a presence an allergic reaction in a subject. The methods include transmitting an ultrasound wave to an area when an ultrasound probe is positioned on to the area of a subject following exposure of the subject to a potential allergen, generating information describing a change in a circulatory system of the subject based on the Doppler information received by the probe, and detecting a food allergy based on processing the information. Non-transitory computer-readable media and apparatuses for methods of the present disclosure are also disclosed.
A processor-implemented system and method for digital aligner simulation include determining axial plane values for at least a group of teeth and a coordinate system. A crown location is determined using the coordinate system. An attachment at the crown location is determined for a digital aligner to be provided in a physical format for the group of teeth. A digital penetration is determined between the digital aligner and the tooth. At least a finite element analysis is applied to the model to determine the force system delivered to the tooth/teeth. The center of rotation, and axis of rotation and therefore the whole movement description is calculated. At least one variation to the attachment or the digital aligner is provided based in part on the orthodontic data.
A61C 7/08 - Appareils de contention du type épousant la forme de la bouche
A61C 7/00 - Orthodontie, c.-à-d. obtention ou maintien de la position désirée des dents, p. ex. par redressage, nivellement, ajustement, séparation, ou par correction des malocclusions
G06F 30/27 - Optimisation, vérification ou simulation de l’objet conçu utilisant l’apprentissage automatique, p. ex. l’intelligence artificielle, les réseaux neuronaux, les machines à support de vecteur [MSV] ou l’apprentissage d’un modèle
In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.
The disclosure is related to a system and method for operating a traction device to detect blood flow patterns in a subject for managing neuropathy related conditions through intraneural facilitation (INF). According to an embodiment, the INF system and method rely on the traction device for positioning the subject in one or more positions, and a processing device for processing intervening signals obtained by a probe positioned on the subject. The signals received from the probe may be used to determine a two dimensional (2D) plane blood flow pattern. Detected changes in the measured blood flow may be used to determine if further traction device positions are required to ensure that the intervening signals demonstrate normal blood flow patterns with improvements to the neuropathy condition. The 2D flow pattern may calculate at least one of Volume Flow (VF) and Pulsatility Index (PI) for each set of signals received.
A pathology grossing tool having an elevated base having a cutting surface positioned a predetermined height above a bottom surface of the elevated base, and a grossing cap operable to be disposed over at least a portion of the cutting surface, the grossing cap having a sidewalls extending along the predetermined height. A groove formed in the grossing cap operable to expose the cutting surface and a membrane receiving area is formed between the cutting surface and the grossing cap when the grossing cap is operably disposed over at least the portion of the cutting surface.
Compositions can be used to stimulate growth of a hair shaft from a hair follicle. These compositions can include methylated polynucleotides useful in treatment of autoimmune diseases or conditions, including those, such as alopecia areata, that result in hair loss.
Compositions for the treatment or prevention of multiple sclerosis are provided. In some embodiments, the composition comprises an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) protein, wherein the peptide activates regulatory T cells. In some embodiments, the composition comprises dendritic cells pulsed with a MOG peptide that activates regulatory T cells. In some embodiments, the peptide activates HLA-E-restricted regulatory CD8+ T cells.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
An evacuation dam apparatus including a frame having a top frame member, a bottom frame member, and two side frame members. A working area formed by the frame, a plurality of ports adjacent the working area, an outlet fluidly coupled with the plurality of ports. A fluid flow from at least a portion of the plurality of ports to the outlet forms a fluid flow path across the working area and at least a portion of the fluid flow path is formed within the frame.
The present disclosure relates to an anatomically aligned prosthetic ankle with a passive assist and associated methods. The prosthetic ankle includes a talus movably coupled to a tibia section by a connector about which the talus is pivotal such so during locomotion by a user of the prosthetic ankle. The passive to assist provides a selected dorsi-flexion force to aid in the push-off or pre-swing phases of gait for the user.
The disclosure includes embodiments of an apparatus, a device, and methods to transform an infant feeding bottle into an infant gavage feeding apparatus. According to an embodiment, an infant gavage feeding apparatus can include an infant feeding bottle, a gavage milk delivery component, a retaining ring, and a cord component. In another embodiment, infant milk dual-delivery device to transform an infant feeding bottle to an alternate nipple feeding and gavage feeding apparatus includes a gavage milk delivery component, a retaining ring, and a nipple receiving component. The gavage milk delivery component and the nipple receiving component can be positioned in a branched or a stacked configuration. The device can include a flow closure component and a controller to transition the milk flow for a gavage feeding and nipple feeding. The device can include a funnel to allow milk in the nipple to flow back into the infant feeding bottle.
A61J 7/00 - Dispositifs pour administrer les médicaments par voie buccale, p. ex. cuillèresDispositifs pour compter les pilulesDispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments
Provided here are methods of treating Niemann-Pick disease type C (NPC) in a subject or delaying the onset of NPC in a subject by administering to the subject an immunomodulator, or a modulator of amyloid precursor protein (APP) function, or a combination thereof.
An evacuation dam apparatus including a frame having a top frame member, a bottom frame member, and two side frame members. A working area formed by the frame, a plurality of ports adjacent the working area, an outlet fluidly coupled with the plurality of ports. A fluid flow from at least a portion of the plurality of ports to the outlet forms a fluid flow path across the working area and at least a portion of the fluid flow path is formed within the frame.
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE (USA)
Inventeur(s)
Cao, Huynh
Xu, Yi
Payne, Kimberly
Baylink, David
Abrégé
In one aspect, engineered hematopoietic stem cells comprising a heterologous expression cassette are provided. In some embodiments, the expression cassette comprises a promoter operably linked to a polynucleotide that encodes a 1α-hydroxylase protein, wherein the 1α-hydroxylase protein is human cytochrome P450 family 27 subfamily B member 1 (CYP27B1).
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE (USA)
THE UNITE STATES OF AMERICA AS REPRESENTED BY UNTED STATES DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Xiaobing, Zhang
Baylink, David
Chen, Wanqui
Lau, Kin-Hing William
Abrégé
In one aspect, anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided. In some embodiments, the anabolic agent fusion protein comprises a platelet derived growth factor (PDGF) or a fibroblast growth factor (FGF) and an Asp-Ser-Ser tripeptide (DSS) repeat sequence. In another aspect, methods of promoting bone growth and methods of treating a fracture using anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
C07K 14/49 - Facteur de croissance dérivé des plaquettes [PDGF]
C07K 14/50 - Facteur de croissance des fibroblastes [FGF]
C07K 5/09 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
26.
Computer-supported intraneural facilitation for vascular changes
The disclosure is related to a system and method for operating a traction device to detect blood flow patterns in a subject for managing neuropathy related conditions through intraneural facilitation (INF). According to an embodiment, the INF system and method rely on the traction device for positioning the subject in one or more positions, and a processing device for processing intervening signals obtained by a probe positioned on the subject. The signals received from the probe may be used to determine a two dimensional (2D) plane blood flow pattern. Detected changes in the measured blood flow may be used to determine if further traction device positions are required to ensure that the intervening signals demonstrate normal blood flow patterns with improvements to the neuropathy condition. The 2D flow pattern may calculate at least one of Volume Flow (VF) and Pulsatility Index (PI) for each set of signals received.
In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.
Systems and methods for identifying abnormal movements or tremors in one or more human subjects. Kinetic and/or electromyographic sensors are employed in detection hardware to detect voluntary and involuntary movements. The data collected from such voluntary and involuntary movement detection can be further processed and compared to baseline data to identify and distinguish abnormal movements from normal movements. The identification of abnormal movements may indicate a neurodegenerative disorder.
Gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
31.
ENGINEERED HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE (USA)
Inventeur(s)
Cao, Huynh
Xu, Yi
Payne, Kimberly
Baylink, David
Abrégé
In one aspect, engineered hematopoietic stem cells comprising a heterologous expression cassette are provided. In some embodiments, the expression cassette comprises a promoter operably linked to a polynucleotide that encodes a 1α-hydroxylase protein, wherein the 1α-hydroxylase protein is human cytochrome P450 family 27 subfamily B member 1 (CYP27B1).
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
32.
Methods and systems for implant identification using imaging data
Embodiments provide techniques, including systems and methods, for processing imaging data to identify an installed component. Embodiments include a component identification system that is configured to receive imaging data including an installed component, extract features of the installed component from the imaging data, and search a data store of components for matching reference components that match those features. A relevance score may be determined for each of the reference components based on a similarity between the image and a plurality of reference images in a component model of each of the plurality of reference components. At least one matching reference component may be identified by comparing each relevance score to a threshold relevance score and matching component information may be provided to an end-user for each matching reference component.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61C 8/00 - Moyens destinés à être fixés à l'os de la mâchoire pour consolider les dents naturelles ou pour y assujettir des prothèses dentairesImplants dentairesOutils pour l'implantation
The disclosure includes embodiments of an apparatus, a device, and methods to transform an infant feeding bottle into an infant gavage feeding apparatus. According to an embodiment, an infant gavage feeding apparatus can include an infant feeding bottle, a gavage milk delivery component, a retaining ring, and a cord component. In another embodiment, an infant milk dual-delivery device to transform an infant feeding bottle to an alternate nipple feeding and gavage feeding apparatus includes a gavage milk delivery component, a retaining ring, and a nipple receiving component. The gavage milk delivery component and the nipple receiving component can be positioned in a branched or a stacked configuration. The device can include a flow closure component and a controller to transition the milk flow for a gavage feeding and nipple feeding. The device can include a funnel to allow milk in the nipple to flow back into the infant feeding bottle.
A61J 7/00 - Dispositifs pour administrer les médicaments par voie buccale, p. ex. cuillèresDispositifs pour compter les pilulesDispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments
A61J 9/08 - Couvercles de protection pour biberons
A61J 11/04 - Tétines avec système de fixation aux biberons
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE (USA)
LOMA LINDA UNIVERSITY (USA)
Inventeur(s)
Baldwin, Dalton Duane
Yeo, Alexander
Martin, Jacob
Abrégé
A needle access assembly and method for obtaining percutaneous needle access with little or no fluoroscopy. The method can include selecting a target for percutaneous access, directing a laser guide at a desired needle-insertion angle and in line with the selected target, aligning the needle access assembly with the laser, and inserting the needle into the target.
A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 90/13 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule guidés par la lumière, p. ex. pointeurs lasers
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 1/307 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'appareil urinaire, p. ex. urétroscopes, cystoscopes
A61B 1/018 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments caractérisés par les conduits internes ou par leurs accessoires destinés à recevoir des instruments
A61B 6/12 - Agencements pour détecter ou localiser des corps étrangers
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
35.
SYSTEMS AND METHODS RELATED TO WELLNESS MAP FOR PROMOTING HEALTH OF PATIENTS
Systems and methods related to wellness map for promoting heath of patients. In some embodiments, a health-promotion system can include a processing device configured to identify a patient, and identify one or more health conditions or diseases associated with the patient. The health-promotion system can be further configured to determine a location of the patient, and identify one or more health-promoting resources based on the location of the patient and the one or more health conditions or diseases associated with the patient. The health-promotion system can be further configured to provide individualized information including one or more geographical locations of the health-promoting resources.
A computed tomography (CT) system can generate an image of an object based on a partial scan over a range of angles. Some embodiments of a CT system can determine a partial- scan orientation based at least in part on image data obtained from a preliminary and/or surface scan of the object. The partial-scan orientation can include a range of angles over which the CT system will perform the CT scan. In some embodiments, the range of angles is comprised of one contiguous range of angles. In some embodiments, the range of angles can comprise two or more noncontiguous ranges of angles. In certain embodiments, the image generated has a higher spatial resolution than an image corresponding to a partial scan over a different range that is similarly sized as, but differently oriented from, the first range.
Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response.
A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A device and method for reducing unnecessary ionizing radiation to patients undergoing a voiding cystourethrogram (VCUG) is provided. The device can include a sensor which detects patient voiding and then actuates an alarm that alerts the radiologist to begin taking x-ray images of the patient. The device can be configured so that the sensor directly actuates a fluoroscopy machine to begin taking x-ray images of the patient once the sensor detects the patient has begun voiding.
A61F 13/42 - Garnitures absorbantes, p. ex. serviettes ou tampons hygiéniques pour application externe ou interne au corpsMoyens pour les maintenir en place ou les fixerApplicateurs de tampons avec un indicateur ou une alarme d'humidité
The therapeutic treatment of a patient using intensity-modulated proton therapy is described. In one example, a method of creating a proton treatment plan is presented that divides volumes of interest into sub-volumes, applies dose constraints to the sub-volumes, finds one or more feasible configurations of a proton therapy system, and selects a proton beam configuration that improves or optimizes one or more aspects of proton therapy. In some implementations, the method of dividing volumes into sub-volumes includes creating fractional sub-volumes based at least in part on proximity to a target volume boundary. In some implementations, the method of finding an improved or optimal proton beam configuration from a set of feasible configurations includes finding a minimum of a cost function that utilizes weighting factors associated with treatment sites.
The United States of America as represented by the Department of Veteran Affairs (USA)
Loma Linda University (USA)
Inventeur(s)
Baylink, David
Lau, Kin-Hing William
Chen, Wanqiu
Zhang, Xiao-Bing
Abrégé
Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
42.
Composition, preparation, and use of chitosan shards for biomedical applications
A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
A61L 2/14 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du plasma, c.-à-d. des gaz ionisés
B29C 43/00 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet
A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
A powder chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A powder chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ- irradiation, treating under a nitrogen plasma, or both.
A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both. A treated thin chitosan material can be utilized to control bleeding and assist in treatment and healing during a surgical procedure, including laparoscopic partial nephrectomy.
A treatment for reducing brain or other injury that can be used before, during, or after a surgical treatment or other injury to the brain to decrease or prevent subsequent damage. Injury to the brain during surgery or from other trauma can create elevations in brain edema and blood-brain barrier disruption thereby decreasing neurological recovery and patient outcomes. Treatment of the brain with venom, including snake venom, prior to or after injury can reduce the bleeding, swelling, and/or inflammation that results from the trauma. These pre-conditioning and/or rapid-conditioning treatments of the brain with venom can reduce brain edema and blood-brain barrier disruption and improve patient outcomes.
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
A61L 2/14 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du plasma, c.-à-d. des gaz ionisés
B29C 43/00 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet
A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
A61L 24/00 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
B29C 43/56 - Moulage par pressage sous conditions particulières, p. ex. sous vide
49.
Use of nitrite salts for the treatment of cardiovascular conditions
The United States of America as represented by the Secretary of the Department of Health and Human Services (USA)
The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Acting through the Louisiana State University Health Sciences Center (USA)
The UAB Research Foundation (USA)
Loma Linda University (USA)
Wake Forest University (USA)
Inventeur(s)
Gladwin, Mark T.
Schechter, Alan N.
Lefer, David J.
Patel, Rakesh P.
Hunter, Christian J.
Power, Gordon G.
Kim-Shapiro, Daniel B.
Pluta, Ryszard Marek
Oldfield, Edward H.
Cannon, Iii, Richard O.
Abrégé
It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
A microfibrillar high molecular weight chitosan-based textile can be used as a hemostat. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan textile. A single or multiple such treatments may be employed. For example, the chitosan textile may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61L 2/20 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances gazeuses, p. ex. des vapeurs
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61L 2/14 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du plasma, c.-à-d. des gaz ionisés
51.
SYSTEMS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
A chitosan material is treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan, and the chitosan material is formulated into a hydrogel which can be utilized as a drug delivery vehicle for medicaments or therapeutic agents to treat certain conditions, such as cancers.
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
Compositions can be used to stimulate growth of a hair shaft from a hair follicle. These compositions can include methylated polynucleotides useful in treatment of autoimmune diseases or conditions, including those, such as alopecia areata, that result in hair loss.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p. ex. contenant des motifs CpG
54.
Compositions and methods for osteogenic gene therapy
The United States of America as represented by the Department of Veteran Affairs (USA)
Inventeur(s)
Lau, Kin-Hing William
Hall, Susan L.
Chen, Shin-Tai
Mohan, Subburaman
Baylink, David J.
Abrégé
The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 14/50 - Facteur de croissance des fibroblastes [FGF]
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A method of analyzing a medical image, where the medical image comprises one or more than one region of interest, and where the method comprises a) providing the medical image comprising a set of actual image values; b) rescaling the actual image values to produce corresponding rescaled image values and to produce a rescaled image from the rescaled image values; c) deriving a histogram of the rescaled image values; d) using the histogram to derive an adaptive segmentation threshold; e) using the adaptive segmentation threshold to recursively split the rescaled image; f) terminating the recursive splitting of the sub(sub) images using one or more than one predetermined criteria; and g) identifying one sub(sub) image in the terminated Hierarchical Region Splitting Tree which comprises the region of interest.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G06K 9/34 - Découpage des formes se touchant ou se chevauchant dans la zone image
According to the improved systems and methods described herein, a patient may be immobilized so that one or both breasts are returned to a known position. Additionally, the improved systems and methods reduce respiratory movement of the breasts. Thus, the immobilization devices and techniques described herein provide accurate and reproducible breast positioning while simultaneously reducing respiratory motion.
Disclosed are systems and methods for characterizing interactions or proton beams in tissues. In certain embodiments, charged particles emitted during passage of protons, such as those used for therapeutic and/or imaging purposes, can be detected at relatively large angles. In situations where beam intensity is relatively low, such as in certain imaging applications, characterization of the proton beam with charged particles can provide sufficient statistics for meaningful results while avoiding the beam itself. In situations where beam intensity is relatively high, such as in certain therapeutic applications, characterization of the proton beam with scattered primary protons and secondary protons can provide information such as differences in densities encountered by the beam as it traverses the tissue and dose deposited along the beam path. In certain situations, such beam characterizations can facilitate more accurate planning and monitoring of proton-based therapy.
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G01N 23/02 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau
58.
Substances and methods for replacing natural tooth material
A substance that sets in a relatively short time for use in general dentistry and in endodontics to replace natural tooth material, the substance comprising untreated mineral trioxide aggregate and milled mineral trioxide aggregate, or comprising untreated mineral trioxide aggregate, milled mineral trioxide aggregate and water. A method of making a substance that sets in a relatively short time for use in general dentistry and in endodontics to replace natural tooth material, the method comprising milling by high shear and impact impingement of particles using high pressure homogenization. A method for use in general dentistry and in endodontics to replace natural tooth material.
A microfibrillar high molecular weight chitosan-based textile can be used as a hemostat. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan textile. A single or multiple such treatments may be employed. For example, the chitosan textile may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61L 2/20 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances gazeuses, p. ex. des vapeurs
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
The therapeutic treatment of a patient using intensity-modulated proton therapy is described. In one example, a method of creating a proton treatment plan is presented that divides volumes of interest into sub-volumes, applies dose constraints to the sub-volumes, finds one or more feasible configurations of a proton therapy system, and selects a proton beam configuration that improves or optimizes one or more aspects of proton therapy. In some implementations, the method of dividing volumes into sub-volumes includes creating fractional sub-volumes based at least in part on proximity to a target volume boundary. In some implementations, the method of finding an improved or optimal proton beam configuration from a set of feasible configurations includes finding a minimum of a cost function that utilizes weighting factors associated with treatment sites.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
Disclosed are systems and methods for characterizing interactions or proton beams in tissues. In certain embodiments, charged particles emitted during passage of protons, such as those used for therapeutic and/or imaging purposes, can be detected at relatively large angles. In situations where beam intensity is relatively low, such as in certain imaging applications, characterization of the proton beam with charged particles can provide sufficient statistics for meaningful results while avoiding the beam itself. In situations where beam intensity is relatively high, such as in certain therapeutic applications, characterization of the proton beam with scattered primary protons and secondary protons can provide information such as differences in densities encountered by the beam as it traverses the tissue and dose deposited along the beam path. In certain situations, such beam characterizations can facilitate more accurate planning and monitoring of proton-based therapy.
A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.
Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
64.
DNA vaccines and methods for the prevention of transplantation rejection
Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response.
Disclosed are systems, devices and methodologies related to calibration of an ion based imaging apparatus such as a proton computed tomography scanner. In some implementations, energy degrader plates having known water-equivalent thickness (WET) values can be introduced to an ion beam to introduce different energy degradation settings. Energy detector responses to individual ions subject to such energy degradation settings can be obtained. Such responses can be normalized and correlated to water-equivalent path lengths (WEPL) of the ions based on the known WET values. Such calibration utilizing degrader plates can be performed relatively quickly and can yield accurate WEPL values that facilitate estimation of, for example, a CT image based on relative stopping power of an object.
According to the improved systems and methods described herein, a patient may be immobilized so that one or both breasts are returned to a known position. Additionally, the improved systems and methods reduce respiratory movement of the breasts. Thus, the immobilization devices and techniques described herein provide accurate and reproducible breast positioning while simultaneously reducing respiratory motion.
An automatic method for detection and quantification of localized sources of magnetic susceptibility in images using a computer with instructions for a parameter module; an image input and filtering module; a second image filtering module; and a pattern quantification module.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
The United States of America as represented by the Secretary of the Department of Health and Human Services (USA)
Wake Forest University (USA)
Loma Linda University (USA)
Inventeur(s)
Gladwin, Mark T.
Schechter, Alan N.
Hunter, Christian J.
Power, Gordon G.
Kim-Shapiro, Daniel B.
Cannon, Iii, Richard O.
Abrégé
It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A01N 37/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe , dans lequel Cn représente un squelette carboné ne comportant pas de cycleLeurs thio-analogues
A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A method of analyzing a medical image, where the medical image comprises one or more than one region of interest, and where the method comprises a) providing the medical image comprising a set of actual image values; b) rescaling the actual image values to produce corresponding rescaled image values and to produce a rescaled image from the rescaled image values; c) deriving a histogram of the rescaled image values; d) using the histogram to derive an adaptive segmentation threshold; e) using the adaptive segmentation threshold to recursively split the rescaled image; f) terminating the recursive splitting of the sub(sub) images using one or more than one predetermined criteria; and g) identifying one sub(sub) image in the terminated Hierarchical Region Splitting Tree which comprises the region of interest.
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
70.
SYSTEMS AND METHODOLOGIES FOR PROTON COMPUTED TOMOGRAPHY
Disclosed are systems, devices and methodologies relating to proton computed tomography. In some implementations, detection of protons can yield track information before and after an object for each proton so as to allow determination of a likely path of each proton within the object. Further, measurement of energy loss experienced by each proton allows determination that a given likely path results in a given energy loss. A collection of such data allows characterization of the object. In the context of energy loss, such a characterization can include an image map of relative stopping power of the object. Various reconstruction methodologies for obtaining such an image, including but not limited to superiorization of a merit function such as total variation, are disclosed. In some implementations, various forms of total variation superiorization methodology can yield excellent results while being computationally efficient and with reduced computing time.
A microfibrillar high molecular weight chitosan-based textile can be used as a hemostat. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan textile. A single or multiple such treatments may be employed. For example, the chitosan textile may be irradiated under nitrogen using γ- irradiation, treated under a nitrogen plasma, or both.
Disclosed are systems, devices and methodologies relating to an ion induced impact ionization detector and uses thereof. In certain implementations, the detector can include a dielectric layer having one or more wells. An anode layer defining apertures to accommodate the openings of the wells can be disposed on one side of the dielectric layer, and a cathode such as a solid resistive cathode can be disposed on the other side so as to provide an electric field in each of the wells. Various design parameters such as well dimensions and operating parameters such as pressure and high voltage are disclosed. In certain implementations, such an ion detector can be coupled to a low pressure gas volume to detect ionization products such as positive ions. Such a system can be configured to provide single ion counting capability. Various example applications where the ion detector can be implemented are also disclosed.
REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE (USA)
Inventeur(s)
Mueller, Claudius
Liotta, Lance
Schrag, Matthew
Kirsch, Wolff, M.
Vinters, Harry, V.
Abrégé
Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful.
The United States of America as represented by the Department of Veterans Affairs (USA)
Loma Linda University (USA)
Inventeur(s)
Lau, Kin-Hing William
Baylink, David J.
Hall, Susan L.
Chen, Shin-Tai
Mohan, Subburaman
Abrégé
The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
A01K 67/00 - Élevage ou obtention d'animaux, non prévus ailleursNouvelles races ou races modifiées d'animaux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
75.
DEVICES AND METHODS FOR PERFORMING PERCUTANEOUS SURGICAL PROCEDURES
A guidewire or a catheter with a stiffness that can be varied during use inside a human body, where the guidewire or the catheter comprises a magnetorheological fluid. A guidewire comprising a proximal section, a distal section, and an intermediate section connecting the proximal section and the distal section, where the intermediate section comprises a longitudinal axis, and the distal section comprises a longitudinal axis, and where the longitudinal axis of the distal section can be coincident with the longitudinal axis of the intermediate section or can be controllably made non-coincident with the longitudinal axis of the intermediate section during use inside a human body, and the guidewire further comprises a plurality of piezoelectric cores and one or more than one piezoelectric strut.
Mammalian host cells for use in a cell-mediated tranfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of downregulating a chosen target gene. Living cells expressing the target gene are then exposed to the ACs. The ACs are processed by the living cells, and the RNAi molecule in the ACs downregulates the expression of the target gene in living cells.
Systems and methods (200) for characterizing spatial distortions in location data determined by an imaging system (102), for example as employed in imaged guided therapy A three dimensional phantom (104) is custom formed (204, 206, 210, 212, 214) for a desired imaging space (120) of a given imaging system (102) The phantom (104) includes a large plurality of control points (105) fixed rigidly in space to a high degree of known accuracy The phantom (104) is fixed to a stereotactic frame (108) defining a known calibrated reference or zero and imaged (216) An algorithm (218) customized for the phantom (104) determines the spatial locations of the control points (105). A (comparison 220) is made between the known and the determined spatial locations for at least a subset of the control points (105) The (comparison 220) results in indicia for any determined spatial distortions observed.
A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)
78.
SYSTEMS AND METHODS FOR PARTICLE RADIATION ENHANCED DELIVERY OF THERAPY
Systems and methods for enhancing the selective targeting of agents (204) for preferential action at a target with reduced action with healthy tissue distal the target tissue. One or more agents (204) can be combined with nano scale structures/particles (202) for delivery to the target tissue. Appropriate bombardment with accelerated particle radiation, such as proton radiation, induces the release of the agents (204) at the target site. Nano carriers can be combined with therapeutic and/or imaging enhancement agents (204). Imaging of the target tissue can provide a verification of the delivered dose of particle radiation. Nanocarriers can be provided with an outer shell selected for biocompatibility and durability in the in vivo environment and further selected to provide a feedback mechanism in the treatment environment to accelerate the release of the agent (204) and reduce a total radiation dose needed for that release.
A substance or a composition for preventing, delaying the onset of or treating one or more than one immune-mediated inflammatory disorder in an organism who is susceptible to developing the immune-mediated inflammatory disorder, who is developing the immune-mediated inflammatory disorder or who has the immune-mediated inflammatory disorder. A method of preventing, delaying the onset of or treating an organism who is susceptible to developing the immune-mediated inflammatory disorder, who is developing the immune-mediated inflammatory disorder or who has the immune-mediated inflammatory disorder.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
80.
Substances for preventing and treating autoimmune diseases
A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ΔBCL-2.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A breathing gas delivery system and method provides a flow of breathing gas to a patient. The gas flow is purposely interrupted for the patient's exhale phase in order to minimize irritation and injury to nasal tissues due to constant, uninterrupted flows. Embodiments include an oscillating ball valve that interrupts oxygen supply during the patient's exhale phase, cannula tips that are shaped to minimize trauma, and a sleep apnea treatment system that interrupts breathing gas supply during the patient's exhale phase.
A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase- 1 (HO-I) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 27/00 - Médicaments pour traiter les troubles des sens
83.
DEVICE AND METHOD FOR IMMOBILIZING PATIENTS FOR BREAST RADIATION THERAPY
According to the improved systems and methods described herein, a patient may be immobilized so that one or both breasts are returned to a known position. Additionally, the improved systems and methods reduce respiratory movement of the breasts. Thus, the immobilization devices and techniques described herein provide accurate and reproducible breast positioning while simultaneously reducing respiratory motion.
A mobile telemedicine device for use in disasters and emergency response comprising four or more wheels connected to a drive train and a main compartment. The main compartment comprises an interior portion and an exterior portion and a supplemental compartment connected to the main compartment. Communications ports are connected to the exterior, and the supplemental compartment. Patient care tables are located in the main compartment. A method for using an all terrain mobile telemedicine vehicle, first driving the mobile telemedicine device to a disaster or emergency location and lowering and deploying a vehicle from the storage compartment to search for patients in need of medical services.
A geographical information system ('GIS') for integrating multiple spatial emergency data, multiple non-spatial emergency data or both multiple spatial emergency data and multiple non-spatial emergency data into a real-time GIS for analyzing emergency data. A method for integrating multiple spatial emergency data, multiple non-spatial emergency data or both multiple spatial emergency data and multiple non-spatial emergency data into a real-time GIS for analyzing emergency data.
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Providing information on prostate cancer treatment and treatment alternatives Providing support in the field of prostate cancer, namely, support group services, companionship, counseling, and emotional support
87.
Use of nitrite salts for the treatment of cardiovascular conditions
The United States of America as represented by the Secretary of the Department of Health and Human Services (USA)
The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center (USA)
The UAB Research Foundation (USA)
Loma Linda University (USA)
Wake Forest University (USA)
Inventeur(s)
Gladwin, Mark T.
Schechter, Alan N.
Lefer, David J.
Patel, Rakesh P.
Hunter, Christian J.
Power, Gordon G.
Kim-Shapiro, Daniel B.
Pluta, Ryszard
Oldfield, Edward H.
Cannon, Iii, Richard O.
Abrégé
It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
A method and apparatus for closing a vascular wound includes an apparatus that can be threaded over a guidewire into place at or adjacent the wound. The apparatus includes a chamber that encloses a hemostatic material therein. When the apparatus is positioned adjacent the wound as desired, the hemostatic material is deployed from the chamber. A blocking member distal of the hemostatic material functions as a barrier to prevent the hemostatic material from entering the wound. Blood contacts the hemostatic material, and blood clotting preferably is facilitated by a hemostatic agent within the material. Thus, the vascular puncture wound is sealed by blood clot formation.
The United States Government as represented by the Department of Veterans Affairs (USA)
Northwestern University (USA)
University of South Alabama (USA)
Inventeur(s)
Strong, Donna D.
Linkhart, Thomas A.
Dean, David A.
Abrégé
A plasmid, viral or linear DNA molecule containing a nucleic acid sequence derived from the promoter region of the hCol1α2 gene, which is selectively transported into the nuclei of cells in the osteoblast lineage. The sequence can be used independently as a nuclear entry sequence only, and/or as a nuclear entry sequence without regard to position, in a vector or linear DNA that directs gene expression and nuclear entry. The disclosure further includes a chimeric DNA sequence derived by the addition of osteoblast-specific enhancer sequences to the nuclear entry sequence/promoter sequence, to increase osteoblast-specific expression while retaining osteoblast-specific nuclear import. An enhancer sequence is derived from the promoter region of the human Core Binding Factor alpha 1 (Cbfa1/Runx2) gene. The Cbfa1/Runx2 promoter can be added to the sequence derived from, or alternatively, comprising the promoter region of the hCol1α2 gene. Also provided are methods of use of the novel sequences.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
90.
Substances for preventing and treating autoimmune diseases
A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoinimune disease or who has the autoinimune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ΔBCL-2.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
This invention relates to deployable hemostatic materials comprising chitosan fibers. The hemostatic materials are suitable for use in sealing or controlling active bleeding from artery and vein lacerations and punctures, and for controlling oozing from tissue.
